Maglakelidze Marina,...,(broj koautora 16) (2023) HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma- Overall survival analysis., JOURNAL OF CLINICAL ONCOLOGY, vol. 41, br. , str. 289-289 (Meeting Abstract) 

Tobias Joshua,Kundi Michael,Garner-Spitzer E,Zielinski Christoph,Maglakelidze Marina,Andric Zoran G,Petrovic Z,Nagarkar R,Chawla T,Chong LO,Nixon B,Yavrom S,Ede NJ,Wiedermann Ursula (2023) HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome, ANNALS OF ONCOLOGY, vol. 34, br. , str. S864-S864 (Meeting Abstract) 

Tobias Joshua,Kundi Michael,Garner-Spitzer E,Zielinski Christoph,Maglakelidze Marina,Andric Zoran G,Petrovic Zeljko M,Nagarkar R,Chawla T,Chong LMO,Nixon B,Yavrom S,Ede NJ,Wiedermann Ursula (2023) HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome, ANNALS OF ONCOLOGY, vol. 34, br. , str. S4-S4 (Meeting Abstract) 

Maglakelidze Marina,Ryspayeva D,Andric Zoran G,Petrovic Zeljko M,Bulat IV,Nikolic Ivan V,Chawla T,Nagarkar R,Wiedermann Ursula,Blumenstein BA,Chong LMO,Ede NJ,Nixon B,Good AJ (2022) HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer, ANNALS OF ONCOLOGY, vol. 38, br. 9, str. S1460-S1460 (Meeting Abstract) 

Maglakelidze Marina,...,Andric Zoran G,Nikolic Ivan V,...,Radosavljevic Davorin Z,Petrovic Zoran,...,(broj koautora 17) (2021) A Phase 1b/2 Open-Label Study with Randomization in Phase 2 of Imu-131 Her2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients with Her2/Neu Overexpressing Metastatic Or Advanced Adenocarcinoma of the Stomach Or Gastroesophageal Junction., CANCER RESEARCH, vol. 81, br. 13, str. - (Meeting Abstract) 

Maglakelidze Marina,...,Andric Zoran G,Nikolic Ivan V,...,Radosavljevic Davorin Z,Petrovic Zeljko M,...,(broj koautora 16) (2021) HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction, ANNALS OF ONCOLOGY, vol. 32, br. , str. S154-S154 (Meeting Abstract)